These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 19362054)

  • 1. The multiple facets of mTOR in immunity.
    Weichhart T; Säemann MD
    Trends Immunol; 2009 May; 30(5):218-26. PubMed ID: 19362054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications.
    Weichhart T; Säemann MD
    Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii70-4. PubMed ID: 19022819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RAPping production of type I interferon in pDCs through mTOR.
    Costa-Mattioli M; Sonenberg N
    Nat Immunol; 2008 Oct; 9(10):1097-9. PubMed ID: 18800159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The TSC-mTOR signaling pathway regulates the innate inflammatory response.
    Weichhart T; Costantino G; Poglitsch M; Rosner M; Zeyda M; Stuhlmeier KM; Kolbe T; Stulnig TM; Hörl WH; Hengstschläger M; Müller M; Säemann MD
    Immunity; 2008 Oct; 29(4):565-77. PubMed ID: 18848473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the mTOR signaling network in cancer.
    Chiang GG; Abraham RT
    Trends Mol Med; 2007 Oct; 13(10):433-42. PubMed ID: 17905659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells.
    Schmitz F; Heit A; Dreher S; Eisenächer K; Mages J; Haas T; Krug A; Janssen KP; Kirschning CJ; Wagner H
    Eur J Immunol; 2008 Nov; 38(11):2981-92. PubMed ID: 18924132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antineoplastic effect of proliferation signal inhibitors: from biology to clinical application.
    Bertoni E; Salvadori M
    J Nephrol; 2009; 22(4):457-62. PubMed ID: 19662600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mTOR--beyond transplantation.
    Young DA; Nickerson-Nutter CL
    Curr Opin Pharmacol; 2005 Aug; 5(4):418-23. PubMed ID: 15955739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IGF-1-stimulated protein synthesis in oligodendrocyte progenitors requires PI3K/mTOR/Akt and MEK/ERK pathways.
    Bibollet-Bahena O; Almazan G
    J Neurochem; 2009 Jun; 109(5):1440-51. PubMed ID: 19453943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of PKHD1 may cause S-phase entry via mTOR signaling pathway.
    Zheng R; Wang L; Fan J; Zhou Q
    Cell Biol Int; 2009 Sep; 33(9):926-33. PubMed ID: 19524688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.
    Ronellenfitsch MW; Brucker DP; Burger MC; Wolking S; Tritschler F; Rieger J; Wick W; Weller M; Steinbach JP
    Brain; 2009 Jun; 132(Pt 6):1509-22. PubMed ID: 19416948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
    Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
    Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ribavirin enhances interferon signaling via stimulation of mTOR and p53 activities.
    Su WC; Liu WL; Cheng CW; Chou YB; Hung KH; Huang WH; Wu CL; Li YT; Shiau AL; Lai MY
    FEBS Lett; 2009 Sep; 583(17):2793-8. PubMed ID: 19619545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase.
    Nowak P; Cole DC; Brooijmans N; Bursavich MG; Curran KJ; Ellingboe JW; Gibbons JJ; Hollander I; Hu Y; Kaplan J; Malwitz DJ; Toral-Barza L; Verheijen JC; Zask A; Zhang WG; Yu K
    J Med Chem; 2009 Nov; 52(22):7081-9. PubMed ID: 19848404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoregulatory functions of mTOR inhibition.
    Thomson AW; Turnquist HR; Raimondi G
    Nat Rev Immunol; 2009 May; 9(5):324-37. PubMed ID: 19390566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The multifunctional role of mTOR in innate immunity: implications for transplant immunity.
    Säemann MD; Haidinger M; Hecking M; Hörl WH; Weichhart T
    Am J Transplant; 2009 Dec; 9(12):2655-61. PubMed ID: 19788500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and mechanism of mammalian target of rapamycin in age-related renal cell senescence and organ aging.
    Zhuo L; Cai G; Liu F; Fu B; Liu W; Hong Q; Ma Q; Peng Y; Wang J; Chen X
    Mech Ageing Dev; 2009 Oct; 130(10):700-8. PubMed ID: 19698731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth suppressive cytokines and the AKT/mTOR pathway.
    Kroczynska B; Kaur S; Platanias LC
    Cytokine; 2009; 48(1-2):138-43. PubMed ID: 19682919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infiltration of tumours by macrophages and dendritic cells: tumour-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes.
    Mantovani A; Sozzani S; Locati M; Schioppa T; Saccani A; Allavena P; Sica A
    Novartis Found Symp; 2004; 256():137-45; discussion 146-8, 259-69. PubMed ID: 15027487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.